Search
Pembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigational[A18829] It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages as interchain bonds and 23 interchain bonds. … [F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1.
Synonyms: ABP 234Products: KEYTRUDA 100 MG/4 ML IV INFUZYONLUK COZELTI İÇEREN FLAKON, 1 ADET, KEYTRUDA® 100 MGLornoxicam
go.drugbank.com/drugs/DB06725ApprovedInvestigationalLornoxicam is approved for use in Japan. … Lornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug.
Mixtures: LORNOPAR 8/300 MG EFERVESAN TABLET ,20 ADETCategories: Non COX-2 selective NSAIDS, Cytochrome P-450 SubstratesOxazepam
go.drugbank.com/drugs/DB00842Approved[A203516] It is an active metabolite of both [diazepam] and [temazepam][A39486] and undergoes very little biotransformation following absorption, making it unlikely to participate in pharmacokinetic interactions … Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders.
Categories: Heterocyclic Compounds, 2-RingProducts: OXAZEPAM-NEURAX 10 MG, Praxiten 50 mg - TablettenTrastuzumab emtansine
go.drugbank.com/drugs/DB05773ApprovedInvestigationalTrastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent … T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis.
Categories: HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors, Cytochrome P-450 SubstratesSynonyms: T-DM1Dihydrocodeine
go.drugbank.com/drugs/DB01551ApprovedIllicitIt was marketed in 1911. … It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis
Mixtures: Poly-tussin EXCategories: Heterocyclic Compounds with 4 or More Rings, Cytochrome P-450 SubstratesPyrantel
go.drugbank.com/drugs/DB11156ApprovedVet approvedIn humans, it is administered as pyrantel pamoate [A32282],[A32283],[L1893],[L1898]. … Pyrantel is on the World Health Organization's List of Essential Medicines, which are the safest and most effective medicines required in a functioning health system [L1901], [L1902].
Mixtures: PAMOXPEN - PAMOATO DE PIRANTEL100 MG+ PAMOATO DE OXANTEL 100 MG TABLETAS, Heartgard Plus Chewable Tablet for Dogs - 26 - 50 lbsProducts: KONTIL 250 MG ÇIĞNEME TABLETI, 1000 ADET, KONTIL 250 MG ÇIĞNEME TABLETI, 500 ADETDicloxacillin
go.drugbank.com/drugs/DB00485ApprovedInvestigationalVet approvedOne of the penicillins which is resistant to penicillinase.
Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 CYP3A InducersSynonyms: (2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acidDiflunisal
go.drugbank.com/drugs/DB00861ApprovedDiflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of rheumatoid arthritis and osteoarthritis.
Categories: Non COX-2 selective NSAIDSSynonyms: 2-(hydroxy)-5-(2,4-difluorophenyl)benzoic acid, 5-(2,4-difluorophenyl)salicylic acidAlirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalAlirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of … It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutics. From this family, it was the first agent to receive FDA approval.
Products: PRALUENT 150 MG/ML SC ENJEKSIYONLUK ÇÖZELTI IÇEREN KULLANIMA HAZIR KALEM,2 ADET, PRALUENT 150 MG/ML SC ENJEKSIYONLUK ÇÖZELTI IÇEREN KULLANIMA HAZIR ENJEKTÖR,2 ADETEvolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalIt is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line therapies. … It is a subcutaneous injection approved by the FDA for individuals on maximum statin therapy who still require additional LDL-cholesterol lowering.
Products: REPATHA 140 MG/ML SC ENJEKSIYONLUK COZELTI ICEREN KULLANIMA HAZIR KALEM, 2 ADET, REPATHA® 140 MG/ML